



Darolutamide is an approved therapy for men with non-metastatic castration-resistant prostate cancer (nmCRPC) that delays metastases and extends survival while limiting the burdensome side effects of therapy – allowing patients to continue their active lifestyle without disruption.¹

Addressing unmet medical needs for men with nmCRPC...



Darolutamide...




Darolutamide (Nubeqa[™]) is approved in the U.S., Australia, Brazil, Canada, Japan, China and the European Union. It is under review with other health authorities worldwide.

Forward-Looking Statements

This document may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Oncology Inspired

Phase III clinical trial data supporting use of darolutamide in nmCRPC



Favorable safety profile

Darolutamide plus ADT has demonstrated a **favorable safety profile**, even with a longer treatment duration, as shown in the final pre-specified OS analysis of ARAMIS. The frequency of adverse events (AEs) in men receiving darolutamide plus ADT is **overall comparable to ADT alone with no clinically relevant increases in rates of hypertension, falls or cognitive impairment.**^{1,7}

The most frequent adverse reactions in the darolutamide plus ADT arm that occurred with an absolute increase in frequency of \geq 2% compared to placebo plus ADT, were fatigue/asthenic conditions, pain in extremity, and rash. Discontinuation due to adverse events occurred in 9% of patients in both arms of the study.

References

1. NUBEQA® Summary of Product Characteristics (SmPC), Bayer Pharma AG. 2, Fizazi K, Shore N, Tammela T, et al. Darolutamide In Nonmetastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2019;380(7). 3. Kirby M. et al. Characteristing the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(1):1130-1192. doi:10.1111/j.1742-1241.2011.02799. 4. Hong J, Kim Y et al. Nonmetastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2019;380(7). 3. Kirby M. et al. Characteristing the castration-resistant prostate cancer, N Engl J Med. 2014;55(3):153. doi:10.4111/kju.2014.55.3.153. 5. Hussain, M., Fizazi, K., Saad, F, et al. Enzalutamide in mem with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2014;351:1502-12. doi:10.1056/NEJMoa040720. 8. ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (ARASENS). Available at: https://clinicaltrials.gov/ct2/showNCT0299902. Last Accessed: December 2020. 9. Fizazi, Karim; Shore, Neal; Tammela, Turo, et al. Nonmetastatic, Castration-Resistant Prostate Cancer (mCRPC). American Society of Clinical Oncology Annual Meeting 2019; May 31, 2019; Chicago, IL. Abstract 5000. 11. Zurth, C, Koskinen, M, Fricke, R et al. Drug-Drug Interaction Potential of Darolutamide: In Vito and Clinical Studies. Eur J Drug Metab Pharmacokinet. 2019; 44(6); 747-759. 12. Zurth C, Sandmann S, Trummel D, et al. Higher blood-brain barrier penetration of [14C]parulutamide eompared to [14C]Darolutamide (DAPO) on pacinity of Clinical Oncology Annual Meeting 2019; May 31, 2019; Chicago, IL. Higher blood-brain barrier penetration of [14C]parulutamide eompared to [14C]Darolutamide in rats using whole-body autoradiography. ASCO GU. Abstract 156. 13. Williams S. Mazibuko N, O'Daly O. Analysis of cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide ENZA) compared to darolutamide (DAPO) on pacentic section 2009; San Francisco, CA; Abstract 326.

Oncology Inspired